Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of CR11342ApublicationCriticalpatent/CR11342A/es
C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
C07D471/04—Ortho-condensed systems
Landscapes
Chemical & Material Sciences
(AREA)
Organic Chemistry
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Nitrogen Condensed Heterocyclic Rings
(AREA)
Abstract
Los compuestos de la formula I: en forma libre o de sal de solvato, en donde R1, R2, R3 y R20 tienen los significados indicados en la memoria descriptiva, son utiles para el tratamiento de enfermedades mediadas por el receptor de ALK-5 y/o ALK-4.
CR11342A2007-10-172010-03-26Derivados de Imidazo [1,2-A]-Piridina Utiles como Inhibidores de Cinasa Tipo Activina (ALK)
CR11342A
(es)
Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm)
Compuestos derivados de pirrolo[2,3-d]pirimidina; inhibidores de limk2; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos inflamatorios, glaucoma, neurodegeneracion, entre otras.